fluconazole + pacritinib

Fluconazole + pacritinib is a combination of two pharmaceutical agents with distinct mechanisms of action. Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 enzyme 14α-demethylase, thereby disrupting ergosterol synthesis and compromising fungal cell membrane integrity. It is primarily used to treat systemic and superficial fungal infections, including various forms of candidiasis and cryptococcal meningitis[1][8]. Pacritinib is an oral small molecule kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis in adults with significantly reduced platelet counts. Pacritinib selectively inhibits Janus kinase 2 (JAK2), FMS-like tyrosine kinase 3 (FLT3), interleukin-1 receptor-associated kinase 1 (IRAK1), and colony-stimulating factor 1 receptor (CSF1R) kinases, but lacks significant JAK1 inhibition at clinically relevant concentrations[2][4][6]. The combination may be considered in clinical scenarios where both antifungal prophylaxis/treatment and myelofibrosis management are required.

Other names

none